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Abstract
Introduction: EUS-guided ethanol ablation of insulinoma is a new method of treatment of this neuroendocrine tumour. Ablation is rec-
ommended in patients who are poor surgical candidates or refuse surgery. We present a case of an 81-year-old female with symptomatic 
insulinoma, treated successfully with EUS-guided alcoholic ablation, along with a literature review including 28 other previously described 
cases. The effectiveness, safety of the therapy, and technical procedure-related issues are summarised. To the best of our knowledge, this 
is the first described case of successful insulinoma EUS- guided ablation in Poland.
Material and methods: We searched the PubMed/Medline database to identify cases of EUS-guided alcoholic ablation. Our analysis 
included 14 articles (case reports or case series), with a total of 27 patients and 31 tumours described, published before February 2017.
Results: The described tumours were relatively small (mean 13 mm), and the most common location was pancreatic head. The mean ethanol 
volume injected to the tumour was 1.8 ml and the concentration of infused alcohol varied from 95% to 98%.Side effects were observed in six 
cases; apart from one, they were mild and self-limiting. There was only one severe adverse event, treated conservatively with success. The median 
follow-up was 14.4 months (2–55 months). In all described cases ablation led to improvement of the symptoms and normalisation of glycaemia. 
Conclusions: The EUS-guided alcoholic ablation of insulinoma is a safe and effective method of treatment in patients who are poor surgi-
cal candidates and/or refuse surgery. The adverse effects are rare and mild and were observed when the volume of injected ethanol was 
equal to or above 3.0 ml. However, the data is limited, the follow-up is relatively short, and prospective studies are needed to confirm 
the long-term effects of treatment. The study shows also that there are important procedural differences (concentration and volume 
of alcohol, needle gauge, number of sessions) between the endoscopists, which should be specified. (Endokrynol Pol 2017; 68 (4): 472–479)
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Streszczenie 
Wstęp: Przedstawiono 81-letnią chorą z objawowym guzem insulinowym głowy trzustki. Pacjentka, z uwagi na liczne choroby współ-
istniejące, została zdyskwalifikowana z leczenia chirurgicznego. Leczona diazoksydem, ciągłymi wlewami z glukozy, analogami somato-
statyny bez istotnej poprawy(obserwowano działania niepożądane). Następnie pod kontrolą EUS wykonano alkoholową ablację zmiany. 
Nie obserwowano powikłań. Odstawiono diazoksyd, obserwując normalizację glikemii. Pacjentka w 4-letniej obserwacji pozostaje bez 
objawów klinicznych hipoglikemii. Według naszej wiedzy jest to pierwszy opisany przypadek skutecznej alkoholowej ablacji guza 
insulinowego w Polsce. W pracy przeprowadzono przegląd literatury i podsumowanie wcześniej przeprowadzonych i opisanych zabie-
gów alkoholowej ablacji guzów insulinowych, ze szczególnym naciskiem na skuteczność i bezpieczeństwo, czas obserwacji po leczeniu 
i szczegóły techniczne przeprowadzenia procedury.
Materiał i metody: Przeszukano bazę Pub Med/Medline, aby zidentyfikować opisane przypadki alkoholowej ablacji guza insulinowego 
trzustki. Do analizy włączono 14 artykułów opublikowanych przed końcem lutego 2017, w których opisano łącznie 27 przypadków i 31 
guzów insulinowych.
Wyniki: Opisane guzy były stosunkowo małymi zmianami (średnio 13 mm), ich najczęstsza lokalizacją była głowa trzustki. Średnia objętość 
podawanego alkoholu to 1,8 ml, a stężenie wynosiło 95–98%. Efekty uboczne obserwowano w 6 przypadkach, poza jednym były one łagodne 
i ustępowały samoistnie. Zaobserwowano tylko jedno poważne powikłanie leczone zachowawczo z sukcesem. Średni czas obserwacji pacjenta 
wyniósł 14,4 miesiąca (od 2 do 55 miesięcy). U wszystkich opisanych chorych ablacja doprowadziła do ustąpienia objawów i normalizacji glikemii.
Wnioski: Alkoholowa ablacja guza insulinowego trzustki pod kontrolą EUS jest bezpieczną i skuteczną metoda leczenia tego guza 
u pacjentów z przeciwwskazaniami do zabiegu lub takich, którzy nie godzą się na zabieg. Większość powikłań ma charakter łagodny i były 
one obserwowane, gdy objętość podawanego do guza etanolu przekraczała 3,0 ml. Krótki czas obserwacji pacjentów i niewielka liczba 
opisanych przypadków, sprawiają że konieczne jest zaplanowanie badań prospektywnych, które mogłyby potwierdzić długoterminowe 
efekty leczenia. Analiza pokazuje również, że występują istotne różnice pomiędzy endoskopistami w zakresie sposobu przeprowadzenia 
samej procedury (stężenie i objętość alkoholu, rozmiar igły, liczba sesji). Powinno dążyć się do sprecyzowania sposobu jej wykonania. 
(Endokrynol Pol 2017; 68 (4): 472–479)
Słowa kluczowe: insulinoma, alkoholowa ablacja, EUS
Krzysztof Dąbkowski, PhD, Department of Gastroenterology,Pomeranian Medical University, Unii Lubelskiej 1, 71–252 Szczecin, tel.: +48 
503–709–056, fax: (091) 425–32–11, e-mail: dabkowskikrzysztof@wp.pl
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and parathyroid hormone tests were all within normal 
limits. Laboratory tests showed elevation of chromogra-
nin A concentration. Table I presents the results of the 
patient’s hormonal assessments. 
Computed tomography (CT), showed a small tumour 
measuring 15 × 10 mm located in the pancreatic head, 
and a positron emission tomography (PET) scan with 
use of somatostatin analogues (labelled with gallium-68) 
demonstrated increased metabolic activity in the same 
area (Fig. 2). There was no evidence of metastases. The 
patient was disqualified from surgery because of age and 
Introduction
Insulinoma is not only the most common functioning 
neuroendocrine pancreatic tumour but also the most 
common cause of endogenous hyperinsulinaemic hy-
poglycaemia [1]. The basic method of treatment remains 
surgery. However, especially in older individuals, it is 
related to significant risk of complications and death. 
Conservative treatment with use of diazoxide is not al-
ways effective, and the adverse effects are often observed 
[2]. Therefore, new methods of treatment are proposed 
with use of somatostatin analogues, mTOR inhibitor 
(everolimus), tyrosine kinase inhibitor (sunitinib), peptide 
receptor radionuclide therapy (PPRT), chemoembolisa-
tion, and radiofrequency or alcoholic ablation [3–11].
We present a patient with insulinoma, who because 
of age and coexisting comorbidities was disqualified 
from surgery. The patient was treated successfully with 
a new and promising method: EUS-guided alcoholic 
ablation. The patient remains free from symptoms after 
four-year observation. A review of the literature with 
special focus on the effectiveness/safety of therapy and 
technical procedure-related issues was performed.
Case report
An 81-year-old female patient with a history of insu-
linoma was admitted to the department of gastroen-
terology for endoscopic alcoholic ablation of the lesion. 
The patient’s main complaints were repetitive diz-
ziness, loss of consciousness, and also numbness of lips 
and tongue for the last five years. The diagnosis of in-
sulinoma was made in the endocrinology department. 
The fasting test was positive and revealed increased 
insulin, C peptide, and decreased glucose level. There 
was no evidence of MEN1 syndrome, and pituitary 
Table I. Hormonal assessment in an 81-year-old insulinoma patient before and after treatment (ablation)
Table I. Ocena hormonalna 81-letniej pacjentki z cukrzycą przed i po leczeniu
Time of assessment Glucose (mg/dl) Insulin (uU/ml) C-Peptide (ng/ml) Chromogranin A (U/l)
Before After Before After Before After Before After
6.00
10.00
14.00
18.00
22.00
29.00
78.00
65.00
69.00
37.00
83.00
91.00
78.00
112.00
96.00
33.31
75.8
4.90
6.30
4.20
4.79
9.97
2.20
3.10
5.30
146.00 12.00
Insulin (n. 2.7–10.4 uU/ml); C-Peptide (n. 0.78–5.19 ng/ml); Chromogranin A (n. 2–18 U/l)
Other markers of neuroendocrine neoplasm (NEN): 
5-HIAA I 24-h Urine 5-HIAA II 24-h Urine Serotonin Gastrin
8.58 mg/24 h (n. 2–9) 8.20 mg/24 h (n. 2–9) 350 ng/ml (n. 40–400) 46.0 uU/ml (n. 28–185)
Figure 1. EUS showing hypoechoic 15 mm tumour located in 
the pancreatic head
Rycina 1. Hypoechogenny guz głowy trzustki o wymiarach 
15 mm w ultrasonografii endoskopowej
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coexisting comorbidities (hypertension, coronary heart 
disease, and chronic obstructive pulmonary disease). 
Thereafter, she was given a recommendation to start 
therapy with diazoxide. However, adverse effects were 
observed (diffuse oedema) and it did not lead to improve-
ment of symptoms or normalisation of glucose levels.
We decided to perform EUS-guided alcoholic abla-
tion of the tumour as an alternative to surgical resection. 
EUS demonstrated a hypoechoic 15 mm lesion located in 
the pancreatic head (Fig. 1). During the examination the 
puncture, using a 22G-needle was performed and 1 ml 
96% ethanol was injected into the lesion (Fig. 2). We ob-
served hyperechoic blush within the tumour (Fig. 3). The 
levels of glycaemia improved (Table I); however, we still 
observed hypoglycaemia-related symptoms. Thereafter, 
the same procedure was repeated after seven days with 
injection of 2 ml of alcohol. There were no procedure-
related complications. The treatment with diazoxide 
was discontinued, and normalisation of glycaemia levels 
were observed during the same hospital stay. Table I 
presents the patients glycaemic profile before and after 
alcoholic ablation. The patient is free from symptoms of 
hypoglycaemia in four-year observation.
Database research
We searched the PubMed/Medline database to identify 
cases of EUS-guided alcoholic ablation. Our analysis 
included 14 relevant articles (case or case series, our 
case) with total of 27 patients and 31 tumours (two 
patients with multiple lesions) published before Febru-
ary 2017. The search terms were “insulinoma ablation” 
and “endoscopic ultrasound guided ethanol ablation 
of tumours”. Twelve articles were written in English 
and two in other languages (Hungarian, Danish). We 
obtained missing information via e-mail directly from 
the authors.
Results
The described tumours were relatively small (mean 
13 ± 5.0 mm) and the most common location (59.3% 
of the tumours) was pancreatic head. Most of the 
patients were females (60.9%) and the mean age of 
the patients was 61 ± 22.6 years (range 26–99 years). 
MEN 1 syndrome was present in four patients (14.9%), 
and most of the tumours were sporadic (85.2%). The 
mean ethanol volume and concentration injected 
to the tumour was 1.8 ml (range 0.2–8 ml), and the 
concentration of infused alcohol varied from 95 to 
98%. The side effects were observed in six cases, they 
were mild, self-limiting, and were observed when 
the volume of ethanol was equal to or above 3.0 ml. 
There was only one severe adverse event: bleeding 
from a duodenal ulcer (in a puncture site), treated 
conservatively with success. The median follow-up 
was 14.4 months. In all described cases, ablation led 
to improvement of the symptoms and normalisation 
Figure 2. EUS-guided ablation. The needle is seen within the 
tumour
Rycina 2. Ablacja endoskopowa. Wprowadzenie igły do guza
Figure 3. EUS-guided ablation. Hyperechoic blush is seen when 
the ethanol is injected
Rycina 3. Ablacja endoskopowa. Hiperechogeniczne ognisko 
widoczne podczas wstrzyknięcia etanolu
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of glycaemia levels. The clinical characteristics of the 
patients and procedure-related issues are presented in 
Table II and III. A summary of the results is presented 
in Table IV.
Discussion
Insulinomas are rare and relatively small neuroen-
docrine tumours mostly located in the pancreas [1]. 
They manifest typically with recurrent episodes of 
hypoglycaemia while fasting and exercising [3]. How-
ever, there is a group of patients (up to 18%) whose 
symptoms appear postprandially [3, 12].The treat-
ment of choice is surgical resection of the tumour or 
symptomatic treatment (small frequent meals and 
diazoxide) in patients who do not qualify for the sur-
gery (i.e. poor general condition, metastatic disease, or 
patient’s refusal of surgical procedure) [3]. The ENETS 
consensus guidelines conclude that in all patients with 
insulinomas (excluding those with metastatic disease) 
Table II. Clinical characteristics of patients
Table II. Charakterystyka kliniczna pacjentów
Authors/Journal Number of 
cases
Age Sex MEN1 Size (mm)/location
Dabkowski K et al. n = 1 81 F – 15/pancreatic head
Burghardt K et al. Diabetes Metab. 2017 [36] n = 1 65 W – 16/head/body
Luo Y et al. Clin Nucl Med. 2017 [37] n = 1 32 M – 27/head
Trikudanthan G et al. Clin Endosc. 2016 [25] n = 1 66 M – 14/head
Paik WH et al. Medicine (Baltimore) 2016 [28] 
n = 3
1/99
2/20
3/32
1/M
2/M
3/M
–
–
–
1/9/head
2/11/head
3/14/head
Park DH et al. Clin Endosc. 2015 [38] 
n = 2
66
27
F
F
_
+
13/head
Multiple lesions:
17/head
10/body
10/tail
Yang D et al. Gastrointest Endosc. 2015 [27] 
n = 4
59
(47–86)
N/A 3 sporadic
1MEN 
N/A
Qin SY et al. Medicine (Baltimore). 2014 [22]
n = 4
1/48
2/56
3/56
4/66
F
F
M
F
1/10/head
2/5.4/head
3/11.8/head/body
4/10/body
Bor R et al. Orv Hetil. 2014 [18] n = 1 83 F – 11/junction of body  
and tail
Lee MJ et al. Intern Med J. 2013 [20] n = 1 26 F + Multiple lesions
17/head
9/body
7/tail
Levy MJ et al. Gastrointest Endosc. 2012 [21] 
n = 5
72
82
80
57
34
F
M
F
F
M
–
–
–
–
+
1/18/head
2/20/tail
3/21/body
4/8/head
5/16/head
Schnack C et al. Ugeskr Laeger 2012 [24] n = 1 89 M – 6/body
Vleegar FP et al. Endoscopy 2011 [26] n = 1 82 F – 9.5/body
Deprez PH et al. 2008 [19] n = 1 78 F – 17/head
Jürgensen C et al. Gastrointest Endosc  
2006 [17] 
n = 1 78 F  - 13/body
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Table III. Procedure-related issues
Table III. Kwestie proceduralne
Authors/Journal No. of 
sessions
Volume of ethanol 
(ml)
Concentration 
(%)
Needle 
(G)
Adverse effects Follow-up 
(months)
Dabkowski K et al. 2 I(session)-1 
II-2 
96 22 No 36 
Burghardt K et al. [36] 1 1 96% N/A No 1.5
Luo Y et al. [37] 1 1.5 99 19 Abd. pain 4 
Trikudanthan G et al. [25] 1 1 99 N/A No 1.5
Paik WH et al. [28] 
1
1/1.2 
2/2.5 
3/3.0 
99 22 1/No
2/No
3/Abd. pain
5.4–55.3
(mean 16.5)
Park DH et al. [38] 2
1
1/I-2.6
II-3.8
2/1.0/head, body
1.2/tail
99
99
99
22
22
22
No
No
12
24
Yang D et al. [27] 05–7.0 
(mean 3.1)
98 22 No 2–30 
(mean 17.3)
Qin SY et al. [22] 
1
Aliquots blush
1/0.5
2/0.25
3/0.5
4/0.3 
95 25
No
1/6 
2/4 
3/5 
4/2 
Bor R et al. [18] 1 3 95 22 Abd. pain 36
Lee MJ et al. [20] 1 1/head, body
2/tail
95 22 No 12
Levy MJ et al. [21] 2 or
3
1/I-0.12
II-0.38
III-0.12
2/I-0.12
II-0.25
3/I-0.95
II-0.28
4/I-3.0
II-1.5
5/I-0.7
II-1.0
0.12–3.0 ml
(mean 0.8 ml)
95
98
98
98
99
22
25
I-25
II-22
22
22
No 13
13
12
38
5
5–38 
(median 13)
Schnack C et al. [24] 1 3.5 98 N/A Mild pancreatitis 2 
Vleegar FP et al. [26] 1 0.3 96 25 No 6 
Deprez PH et al. [19] 1 3.5 98 21.25 ↑ pancreatic 
enzymes, 
hematoma, 
duodenal ulceration 
(Forrest 2a) and 
bleeding
24 
Jürgensen C et al. [17] 1 8 95 Mild pancreatitis 34 
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surgical exploration should be performed, and in pa-
tients with sporadic disease a laparoscopic approach is 
recommended [3].
Surgical treatment is associated with significant 
risk of complications, which limits its use, especially 
in older individuals with comorbidities [13]. The less 
invasive method of treatment is tumour enucleation, 
which is not always possible to perform. However, 
mortality, overall complication rates, and need of 
re-interventions are comparable between standard 
resections and enucleation, while the rate of fistula 
is even higher in the enucleation group [13, 14]. In 
contrast, the incidence of exocrine and endocrine 
insufficiency are significantly higher after Whipple’s 
procedure [13].
In cases of inoperable disease, typically treatment 
with diazoxide is initiated. However, it is not always 
effective, and adverse effects (especially fluid retention 
and hirsutism) are often observed [2]. Recently, novel 
therapies with use of somatostatin analogues, everoli-
mus, sunitinib, peptide receptor radionuclide therapy 
(PPRT), chemoembolisation and radiofrequency and 
alcoholic ablation were proposed [11, 15, 16].
EUS-guided ethanol ablation of pancreatic insu-
linoma is a novel method, first reported by the group of 
Jürgensen C. et al. [17]. The Medline database research 
shows 14 cases or case series of insulinoma EUS-guided 
ethanol ablation [17–27]. Moreover, there are also re-
ports of alcoholic ablation of other pancreatic tumours 
of neuroendocrine and other origin (especially cystic 
pancreatic tumours) [28–30]. Some prospective studies 
are still in progress [29]. 
Database research shows not only safety but also 
efficacy of this procedure (Table II, IV). Most of the de-
scribed tumours were small insulinomas with a mean 
diameter of 13 mm. The volume of injected ethanol 
varied from 0.2 to 8 ml, and some authors decided 
for one session others for two. The concentrations of 
alcohol ranged from 95 to 99%, and the needle gauge 
was between 19 and 25 G. These differences between 
the groups raise important questions about optimal 
procedural issues that are not yet established and about 
the effectiveness and safety of this treatment in larger 
tumours and in non-functioning tumours. 
Yang D. et al. injected 98% ethanol in 0.1 ml repeated 
samples until hyperechoic blush was seen in the tumour 
[27]. Quin S. et al. proposed a formula in which the vol-
ume of injected alcohol in round, regular tumours was 
half of the size of the lesion, while in oval and irregular 
tumours the volume of alcohol should be determined 
by adding the minor and major axis of the lesion [22].
They also reduced the dose of infused alcohol to a half 
or one third when the tumour was located near a vessel 
or pancreatic duct [22]. 
All of the patient’s symptoms and their glycaemic 
profiles improved after the procedure. The longest 
follow-up was 55 months. In functioning tumours 
we can determine the effectiveness of the procedure 
clinically (improvement of symptoms) or by measur-
ing the hormonal activity. In non-functioning tumours 
the issue of follow-up is more complex. Some authors 
performed follow-up EUS (also in insulinoma) and it 
revealed partial or total tumour size regression [17, 
19, 28]. However, we are not able to predict long-term 
results and the risk of development of metastases and 
recurrence of the disease [22, 28, 31, 32]. 
The side effects were generally mild and self-limit-
ing: mild acute pancreatitis, fever, abdominal pain [17, 
18, 22, 28]. Only one described event should be classi-
fied as severe-bleeding from duodenal ulcer (Forrest 
2a) with haematoma, which was treated conservatively 
with proton pump inhibitor [19]. We noticed that the 
adverse events were observed only when the volume of 
injected alcohol was equal to or above 3.0 ml (Table III). 
In our opinion, the strategy described by some authors 
Table IV. Summary of patients’ characteristics and procedure-
related issues
Tabela IV. Charakterystyka pacjentów i kwestie proceduralne
Number of patients 27
Sporadic/MEN1 23/4
(85.2%)/(14.8%)
Number of tumours 31 (two patients with multiple lesions)
Age (years) 61 (mean) ± 22.6
(26–99) (range)
Sex (F/M) 14/9
(60.9%)/(39.1%)
(information about 4 patients N/A)
Size of tumour (mm) 13 ± 5
(5.4–27)
Location (head/body/tail) 16/8/3
(59.3%)/(29.6%)/(11.1%)
(information about 4 tumours N/A)
Volume of ethanol (ml) 1.8 ± 1.8
(0.2–8)
Concentration (%) (95–99)
Follow-up (months) 14.4 ± 14.6
(2–55 months)
Adverse events
Total
Mild
Severe
6 (18.7%)
4 (12.5%)
1 (3.1%)
Effectiveness 27/27 (100%)
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in which ethanol is injected under the control of sight, 
in small aliquots (0.1 ml) until the hyperechoic blush is 
seen within the tumour, is feasible, rational, and safe. 
The volume of alcohol injected to the small tumours 
(as those described) should not exceed 3.0 ml. This 
conclusion is supported by another severe complica-
tion of ablation (of non-functioning neuroendocrine 
tumour) reported by Paik et al. [28]. The injection of 
5.0 ml of alcohol with use of a multi-hole celiac plexus 
neurolysis needle (CPN) resulted in acute pancreatitis 
and 36 days of hospital stay [28]. Therefore, the authors 
recommend use of a single-hole needle in the procedure 
[28]. A relation between the volume of injected ethanol 
and the adverse events was also noted by the authors 
of previously published cases and is amplified by our 
study [28].The risk of development of adverse events 
depends naturally on the experience of the endoscopist. 
The concentrations of ethanol used in the procedure 
were between 95 and 99%. There are sparse data about 
the use of lower concentrations of ethanol. Muscatiello 
et al. described the case of ablation of an endocrine 
tumour, in which a low concentration of alcohol (40%) 
was used. The second session of the procedure ended 
up with ethanol effusion during needle retraction, 
which resulted in pancreatic necrosis, treated with 
laparoscopic necrosectomy [33].
The described tumours were relatively small and 
we do not know much about the safety and efficacy of 
ethanol ablation in larger tumours. Mathers B.W. et al. 
reported successful ablation of large metastatic carcinoid 
lesion (11.4 cm) located in liver hilum. The procedure 
lead to a 36% reduction of tumour size, improvement of 
pain, and decrease of chromogranin level [34].
In our patient, we decided to perform two sessions 
of ablation. The first procedure did not lead to improve-
ment, the patient still suffered from hypoglycaemia-
related symptoms, and the levels of glucose in blood 
were still low. Moreover, our previous, unpublished 
observations showed that one session of ablation was 
not effective (in our previous case, the patient did not 
agree to the second session and she still suffered from 
hypoglycaemia). In our opinion, the decision to perform 
a subsequent procedure should depend on the presence 
of clinical symptoms. Moreover, while deciding on the 
second session, endoscopists should take into account 
the risk of adverse events related to EUS-FNA [35].
Conclusions
EUS-guided alcoholic ablation of insulinoma is safe 
and effective method of treatment (technical success 
in 100%) and is indicated in patients who are poor 
surgical candidates and/or refuse surgery. The adverse 
effects are mild and were observed when the volume of 
injected ethanol was equal to or above 3.0 ml. However, 
the data is limited, the follow-up is relatively short, and 
prospective studies are needed to confirm the long-
term effects of treatment. Moreover, we are not able to 
predict long-term outcomes and the risk of recurrence 
and development of metastases. The study shows also 
that there are important procedural differences (con-
centration and volume of alcohol, number of sessions) 
between the endoscopists, which should be specified. 
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